UNASSIGNED: 7276 Background: Primary goals of therapy for @entity1149 ( @entity1149 ) are an increased survival time, palliation of symptoms, and prolonged @entity1054 ( @entity1054 ). This study was designed to explore if @entity1149 @entity1 (pts) with ECOG @entity13770 and age <= 65 years could benefit from systemic chemotherapy with acceptable @entity137 . METHODS: Fifty-nine eligible pts with stage IIIB (effusion) or stage IV NSCLC were registered on study. @entity1 received @entity1205 ( @entity1205  ) 35 mg/m(2) and @entity3003 AUC=2 on Days 1, 8, and 15 every 28-day cycle (maximum 8 cycles). Endpoints were 1-year survival, @entity5 response, @entity1054 , and safety. RESULTS: Among the 59 eligible pts, 1 never received study drug, 58 pts were evaluable for safety, and 49 for response; 9 pts were non-evaluable due to: palliative XRT (1), withdrawal of consent (2), @entity137 (1 each; @entity1353 , weakness, @entity566 to study drug) and other illness (3). Responses were: 1 CR (2%), 5 PR (10%), 22 @entity168 (45%), and 21 @entity1726 (43%). The 1-year survival was 28%; median survival was 6.0 months (range, <1-24.3). The 1-year progression-free survival was 14% with a median @entity1054 of 3.7 months (range, <1-22.8) and median duration of response for CR+PR was 5.4 months (range, 2.3-9.7). @entity1 received a median of 3 cycles (range, 1-9); 14 pts (24%) had dose reductions, mainly due to @entity137 . The primary Grade 3 or 4 @entity137 were @entity1398 and fatigue (10.2% each), @entity390 (8.5%), @entity2700 (6.8%), and @entity391 (5.1%). All 43 @entity204 were due to @entity1726 . @entity137 of this regimen are comparable to other chemotherapy regimens used in this population, thus it may be an alternative treatment choice for @entity1 with @entity1149 who are <= 65 years and @entity13770 . CONCLUSIONS: These results confirm the relatively poor outcome of @entity13770 pts with @entity1149 . The overall benefit of chemotherapy doublets, compared to monotherapy, in this @entity1 population remains to be proven. Supported by Aventis Pharmaceuticals, Bridgewater, NJ No significant financial relationships to disclose.

A phase II study of weekly @entity1205 and XXXX in stage IIIB (with effusion) or stage IV @entity1149 @entity1 age <65 and performance status 2.

@entity1 :: ('9606', 'Species') :: ['patient', 'Patients', 'patients'] @entity13770 :: ('338412', 'Gene') :: ['PS 2'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities', 'Toxicities'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity2700 :: ('MESH:D003681', 'Disease') :: ['dehydration'] @entity1353 :: ('MESH:D004417', 'Disease') :: ['dyspnea'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity566 :: ('MESH:D006967', 'Disease') :: ['allergy'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['advanced non-small cell lung cancer', 'ANSCLC'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel', 'Taxotere'] @entity168 :: ('MESH:D029461', 'Disease') :: ['SD'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity1726 :: ('OMIM:168600', 'Disease') :: ['PD'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity204 :: ('MESH:D003643', 'Disease') :: ['deaths'] @entity1054 :: ('MESH:D000377', 'Disease') :: ['time to progression', 'TTP']
@entity3003 :: (MESH:D016190,Chemical) :: ['carboplatin']
